- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Pancreatic Cancer, Quality of Life, Small Intestine Cancer
- Interventions
- bowel obstruction management, quality-of-life assessment
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 126
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Celiac Disease
- Interventions
- Mucosal Impedance Catheter, Blood sample
- Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
- Interventions
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obesity, Obesity, Morbid, Obesity Associated Disorder, Bariatric Surgery Candidate, Fistula, Gastric, Roux-en-y Anastomosis Site, Ulcer, Gastric, Abdominal Pain, Abdominal Obesity, Complication of Surgical Procedure, Complication of Treatment, Complication,Postoperative, Weight Gain, Weight Loss, Leak, Anastomotic, Delayed Gastric Emptying Following Procedure
- Interventions
- Primary Obesity Endoscopic Procedures, Endoscopic Revision of Bariatric Surgical Procedures, Bariatric Surgery Procedures, Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction, Intragastric Balloon, Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal, Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy, Aspiration Therapy
- Procedure · Device
- Lead sponsor
- Christopher C. Thompson, MD, MSc
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastroduodenal Ulcer
- Interventions
- Naproxen, Aspirin, Celecoxib, Clopidogrel, Placebo
- Drug
- Lead sponsor
- Research Associates of New York, LLP
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Interventions
- Revita Duodenal Mucosal Resurfacing (DMR), Sham
- Device
- Lead sponsor
- Fractyl Health Inc.
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Newport Beach, California + 24 more
- Conditions
- Gastric Ulcer
- Interventions
- PN400 (VIMOVO), Naproxen
- Drug
- Lead sponsor
- POZEN
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Laparoscopic duodenal exclusion, Conventional Medical Treatment
- Procedure · Other
- Lead sponsor
- McKenzie Health System
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Sandusky, Michigan
- Conditions
- Obesity, Type-2 Diabetes Mellitus
- Interventions
- Loop duodenal switch
- Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
- Interventions
- SGR-1505
- Drug
- Lead sponsor
- Schrödinger, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
- Conditions
- Duodenal Neoplasm, Pancreatic Neoplasm
- Interventions
- Bupivacaine, Hydromorphone, Iopamidol, Liposomal Bupivacaine, Medical Chart Review, Questionnaire Administration, Thoracic Epidural Analgesia, Ultrasound Imaging, X-Ray Imaging
- Drug · Other · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Gastric Ulcer
- Interventions
- PN400 (VIMOVO), PN 400 (VIMOVO)
- Drug
- Lead sponsor
- POZEN
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma, Ampullary Adenocarcinoma
- Interventions
- Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR)
- Device · Drug
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Duodenal Obstruction
- Interventions
- Enteral stenting
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Helicobacter Infections, Gastritis, Peptic Ulcer
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 3
- States / cities
- Miami, Florida • Atlanta, Georgia • Cleveland, Ohio
- Conditions
- Marginal Ulcer
- Interventions
- Omeprazole 40 milligrams
- Drug
- Lead sponsor
- Stephen Firkins
- Other
- Eligibility
- Not listed
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pancreatic or Peripancreatic Lesions, Lesions in the Esophagus, Stomach, Duodenum or Rectum, Mediastinal ( Chest) Masses, Enlarged Lymph Nodes
- Interventions
- Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
- Procedure
- Lead sponsor
- Texas Tech University Health Sciences Center, El Paso
- Other
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Achlorhydria, Gastrinoma, Zollinger Ellison Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Esophagitis, Reflux, Esophagitis, Peptic
- Interventions
- Dexlansoprazole MR, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 100
- States / cities
- Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
- Conditions
- Acute Gastrointestinal Bleeding
- Interventions
- UI-EWD, Conventional therapy
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Voice Disorders, Gastroesophageal Reflux
- Interventions
- Neuromuscular Electrical Stimulation, Unstimulated
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Upper Gastrointestinal Bleeding
- Interventions
- Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation, Clinician Notification with Nurse Facilitation / Patient Activation
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Functional Dyspepsia
- Interventions
- Ketotifen, Placebo
- Drug
- Lead sponsor
- Craig A. Friesen, MD
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1, Functional Pancreatic Neuroendocrine Tumor, Gastric Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Nonfunctional Pancreatic Neuroendocrine Tumor, Thymus Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas